Curanex Pharmaceuticals Inc’s Lock-Up Period To End Tomorrow (NASDAQ:CURX)

Curanex Pharmaceuticals’ (NASDAQ:CURX) lock-up period will end on Monday, February 23rd. Curanex Pharmaceuticals had issued 3,750,000 shares in its initial public offering on August 26th. The total size of the offering was $15,000,000 based on an initial share price of $4.00. After the end of the company’s lock-up period, company insiders and major shareholders will be able to sell their shares of the company.

Analyst Upgrades and Downgrades

A number of brokerages have recently commented on CURX. Weiss Ratings reissued a “sell (e-)” rating on shares of Curanex Pharmaceuticals in a research note on Monday, December 29th. Wall Street Zen downgraded Curanex Pharmaceuticals from a “hold” rating to a “sell” rating in a report on Saturday, November 22nd. One investment analyst has rated the stock with a Sell rating, Based on data from MarketBeat.com, Curanex Pharmaceuticals currently has a consensus rating of “Sell”.

Curanex Pharmaceuticals Price Performance

CURX opened at $0.31 on Friday. Curanex Pharmaceuticals has a 52-week low of $0.26 and a 52-week high of $9.18. The firm’s 50 day moving average price is $0.35. The stock has a market capitalization of $8.79 million and a price-to-earnings ratio of -6.20.

Institutional Inflows and Outflows

A hedge fund recently bought a new stake in Curanex Pharmaceuticals stock. Citadel Advisors LLC bought a new stake in Curanex Pharmaceuticals Inc (NASDAQ:CURX) in the 3rd quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The firm bought 64,067 shares of the company’s stock, valued at approximately $46,000.

About Curanex Pharmaceuticals

Curanex is a developmental stage pharmaceutical company dedicated to discovering, developing and commercializing innovative botanical drugs to treat patients suffering from inflammatory diseases. Our mission is to address significant unmet medical needs and improve patients’ lives by harnessing the power of natural substances. We are dedicated to discovering, developing and commercializing botanical medicines for treating patients with immune and inflammatory diseases and to develop therapies that may offer potential benefits to patients with unmet clinical needs in various fields, such as autoimmune diseases, metabolic diseases and viral infections.